ArticleDiscover oncology2026
Curcumin as a neuroprotective agent against platinum-induced peripheral neuropathy: a double-blind randomized clinical trial.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced peripheral neuropathy (CIPN) particularly from platinum-based agents remains a major dose-limiting complication, impairing patients' quality of life. This double-blind randomized clinical trial evaluated the neuroprotective potential of curcumin, a natural polyphenol with antioxidant and anti-inflammatory properties, in mitigating platinum-induced peripheral neuropathy in cancer patients.
methodsSeventy adult cancer patients with established platinum-induced CIPN were randomly assigned to receive either curcumin (40 mg twice daily) or placebo for four weeks in a double-blind design. Neuropathy symptoms were assessed using the validated QLQ-CIPN20 questionnaire at baseline and during follow-up (days 4, 7, 14, and 28).
resultsOf 70 randomized patients, 65 completed the study (31 in the curcumin group and 34 in the placebo group). By day 28, the curcumin group demonstrated a significant reduction in sensory symptom scores compared with placebo (p = 0.021), along with a decrease in total QLQ-CIPN20 scores (p = 0.0012). No significant changes were observed in motor or autonomic domains.
conclusionCurcumin significantly alleviated sensory symptoms of CIPN, suggesting a potential neuroprotective effect. Although only patient-reported outcomes were evaluated, the results provide preliminary clinical evidence supporting curcumin as a safe adjunctive option for managing CIPN. Future studies incorporating objective neurophysiological or biomarker assessments are warranted to validate these findings.
trial registrationTrial Registry Number (IRCT20191106045356N6|| https://irct.behdasht.gov.ir/ ) with the Clinical Trial Registry 2022-08-29.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.